New Drug: Glofitamab for Large B Cell Lymphoma

  • Study

    Phase 2 study
    Relapsed or refractory DLBCL, transformed follicular lymphoma, high-grade B-cell lymphoma, or primary mediastinal large B-cell lymphoma
    Obinituzumab and Glofitamab (n = 155)


  • Efficacy

    ORR: 52%
    CR: 39%
    1-yr PFS: 37%
    mOS: 4.9 mos
    1-yr OS: 50%


  • Safety

    Any glofitamab-related grade ≥3 AEs: 42%


    • N Engl J Med 2022; 387:2220-2231

    Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    http://doi.org/ 10.1056/NEJMoa2206913

    Reviewed by Elvin Chalabiyev, MD on Sep 23, 2023

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag